SCHEMBL12895097

SCHEMBL12895097

Cc1ccccc1-n1c(Cn2nc(-c3ccc(O)c(Cl)c3)c3c(N)ncnc32)nc2scc(C)c2c1=O

nearest known ligand 0.65

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 19/20 0.65
▸ PIK3CG P48736 9/20 0.65
▸ PIK3CA P42336 7/20 0.65
▸ PIK3CB P42338 7/20 0.65
▸ PRKDC P78527 2/20 0.62
▸ ABL1 P00519 1/20 0.62
▸ SRC P12931 1/20 0.62
▸ MTOR P42345 1/20 0.62
▸ PIK3R1 P27986 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12895088 0.94 PIK3CD (0.64) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL12895071 0.90 PIK3CD (0.69) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL1261217 0.89 PIK3CD (0.78) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL12895092 0.89 PIK3CD (0.62) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL12895087 0.88 PIK3CD (0.72) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL12895075 0.87 PIK3CD (0.68) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL12895085 0.86 PIK3CD (0.64) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL1259614 0.86 PIK3CD (0.78) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL12895094 0.85 PIK3CD (0.66) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC
SCHEMBL12895072 0.85 PIK3CD (0.54) PIK3CDPIK3CGPIK3CAPIK3CBPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3613743-B1 PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES INTELLIKINE LLC (US) 2022-03-16 — — EP disclosed
US-9822131-B2 Certain chemical entities, compositions and methods INTELLIKINE LLC (US) 2017-11-21 — — US disclosed
US-9822131-B2 Certain chemical entities, compositions and methods INTELLIKINE LLC (US) 2017-11-21 — — US disclosed
US-20160185800-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE, INC. 2016-06-30 — — US disclosed
US-20160185800-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE, INC. 2016-06-30 — — US disclosed
US-20140206684-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC (US) 2014-07-24 — — US disclosed
US-20140206684-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC (US) 2014-07-24 — — US disclosed
US-8703777-B2 Certain chemical entities, compositions and methods INTELLIKINE LLC (US) 2014-04-22 — — US disclosed
US-20110046165-A1 CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2011-02-24 — — US disclosed
US-20110046165-A1 CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2011-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206684-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, AKT3, PIK3C2A PIK3CD 7/4885PIK3CG 8/4885PIK3CA 1/4885
US-20160185800-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, AKT3, PIK3C2A PIK3CD 7/4885PIK3CG 8/4885PIK3CA 1/4885
US-20110046165-A1 CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS PIK3CA, AKT3, PIK3C2A PIK3CD 6/4885PIK3CG 15/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback